Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

GW Pharmaceuticals (GWPH) ADS each Representing 12 Shares

Sell:$98.36 Buy:$101.20 Change: $0.15 (0.15%)
NASDAQ:0.24%
Market closed |  Prices as at close on 21 November 2019 | Switch to live prices |
Sell:$98.36
Buy:$101.20
Change: $0.15 (0.15%)
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
Market closed |  Prices as at close on 21 November 2019 | Switch to live prices |
Sell:$98.36
Buy:$101.20
Change: $0.15 (0.15%)
Market closed |  Prices as at close on 21 November 2019 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company is also focused on developing its pharmaceutical product pipelines, which includes Epidiolex for the treatment of Tuberous Sclerosis Complex and RETT Syndrome.

Contact details

Address:
Sovereign House
Vision Park, Chivers Way
CAMBRIDGE
CB24 9BZ
United Kingdom
Telephone:
+44 (1223) 266800
Website:
https://www.gwpharm.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
GWPH
ISIN:
US36197T1034
Market cap:
$3.07 billion
Shares in issue:
370.94 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Geoffrey Guy
    Executive Chairman of the Board
  • Justin Gover
    Chief Executive Officer, Executive Director
  • Adam George
    Chief Financial Officer, Company Secretary, Director
  • Christopher Tovey
    Chief Operating Officer, Executive Director
  • Darren Cline
    Chief Commercial Officer, U.S.

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a SIPP or Fund and Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.